Everything drug pricing and policy, every day
And insurers have (another) terrible, horrible, no good, very bad day
And new research shows that when hospitals join 340B, money flows to investments, not charity care
And almost 20 companies and groups have made their case to the White House on 340B ‘rebate models’
And everyone picked today to go deep on Hims & Hers CEO (and donut magnate) Andrew Dudum
And we have lots of 340B items this week, starting with one provider saying the quiet part out loud about the struggles of retail pharmacy
And highlighting one of the best 340B overview stories I’ve seen in a long time
Plus an IQVIA assessment of the $2,000 Part D cap shows the dramatic impact on oncology patients ... and manufacturers
And an introductory look into a huge question: Will the use of medicines in Medicaid plunge when millions lose coverage?
Plus two academic papers worth reading, one raising concerns about step therapy and one raising concerns about MFN. Lots to be concerned about today!
